Kyntra Bio Inc (NASDAQ:KYNB) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of Kyntra Bio Inc (NASDAQ:KYNB) have earned an average rating of “Moderate Buy” from the five research firms that are currently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, two have given a buy rating and one has assigned a strong buy rating to the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $32.50.

KYNB has been the topic of a number of analyst reports. Weiss Ratings raised shares of Kyntra Bio from a “sell (d)” rating to a “sell (d+)” rating in a report on Friday, August 14th. Oppenheimer began coverage on Kyntra Bio in a report on Monday, July 6th. They set an “outperform” rating and a $35.00 target price for the company. Finally, Rodman & Renshaw initiated coverage on shares of Kyntra Bio in a report on Tuesday, June 9th. They issued a “buy” rating and a $30.00 price target on the stock.

Kyntra Bio Stock Down 3.0%

NASDAQ KYNB opened at $7.78 on Tuesday. The firm has a market cap of $31.51 million, a P/E ratio of 0.17 and a beta of 1.02. The company’s 50 day moving average is $7.27 and its 200-day moving average is $7.13. Kyntra Bio has a 12-month low of $6.32 and a 12-month high of $12.60.

Institutional Trading of Kyntra Bio

An institutional investor recently bought a new position in Kyntra Bio stock. Renaissance Technologies LLC bought a new position in Kyntra Bio Inc (NASDAQ:KYNB) in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund bought 27,481 shares of the company’s stock, valued at approximately $186,000. Renaissance Technologies LLC owned approximately 0.68% of Kyntra Bio as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 72.71% of the company’s stock.

About Kyntra Bio

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.